Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v3-EN | Version v2-FR | |
|---|---|---|
| Language | English | French |
| Date Updated | 2022-02-14 | 2022-02-10 |
| Drug Identification Number | 02449935 | 02449935 |
| Brand name | XIGDUO | XIGDUO |
| Common or Proper name | dapagliflozin and metformin hydrochloride tablets | dapagliflozin and metformin hydrochloride tablets |
| Company Name | ASTRAZENECA CANADA INC | ASTRAZENECA CANADA INC |
| Ingredients | METFORMIN HYDROCHLORIDE DAPAGLIFLOZIN | METFORMIN HYDROCHLORIDE DAPAGLIFLOZIN |
| Strength(s) | 850MG 5MG | 850MG 5MG |
| Dosage form(s) | TABLET | TABLET |
| Route of administration | ORAL ORAL | ORAL ORAL |
| Packaging size | 6 blisters (10 tablets per blister) per carton | 6 blisters (10 tablets per blister) per carton |
| ATC code | A10BD | A10BD |
| ATC description | BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS | BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS |
| Reason for shortage | Delay in shipping of the drug. | Delay in shipping of the drug. |
| Anticipated start date | 2022-02-21 | 2022-02-18 |
| Actual start date | ||
| Estimated end date | Unknown | Unknown |
| Actual end date | ||
| Shortage status | Anticipated shortage | Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments | ||
| Health Canada comments |